Systematic indirect comparison of ospemifene versus local estrogens for vulvar and vaginal atrophy

References

• MacBride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc 2010;85:87–94
   PubMed Web of Science ®Google Scholar
• Archer DF. Efficacy and tolerability of local estrogen therapy for urogenital atrophy. Menopause 2010;17:194–203
   PubMed Web of Science ®Google Scholar
• Goldstein IJ. Recognizing and treating urogenital atrophy in postmenopausal women. Womens Health (Larchmt) 2010;19:425–32
   PubMed Web of Science ®Google Scholar
• Parish SJ, Nappi RE, Krychman ML, et al. Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy. Int J Womens Health 2013;5:437–47
   PubMedGoogle Scholar
• North American Menopause Society. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 2013;20:888–902
   PubMed Web of Science ®Google Scholar
• Rahn DD, Carberry C, Sanses TV, et al. Society of Gynecologic Surgeons Systematic Review Group. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol 2014;124:1147–56
   PubMed Web of Science ®Google Scholar
• Palacios S, Castelo-Branco C, Currie H, et al. Update of management of genitourinary syndrome of menopause. A practical guide. Maturitas 2015;82:308–13
   PubMed Web of Science ®Google Scholar
• Kingsberg SA, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women’s VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med 2013;10:1790–9
   PubMed Web of Science ®Google Scholar
• Nappi RE, Palacios S, Panay N, Particco M, Krychman ML. Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey. Climacteric 2016;19:188–97
   PubMed Web of Science ®Google Scholar
• Senshio (ospemifene) tablets. European Public Assessment Report. European Medicines Agency. London November 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002780/WC500182777.pdf [last accessed 6 Sept 2016]
   Google Scholar
• Rutanen EM, Heikkinen J, Halonen K, Komi J, Lammintausta R, Ylikorkala O. Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial. Menopause 2003;10:433–9
   PubMed Web of Science ®Google Scholar
• DeGregorio MW, Zerbe RL, Wurz GT. Ospemifene: a first-in-class, non-hormonal selective estrogen receptor modulator approved for the treatment of dyspareunia associated with vulvar and vaginal atrophy. Steroids 2014;90:82–93
   PubMed Web of Science ®Google Scholar
• Bachmann G, Lobo RA, Gut R, Nachtigall L, Notelovitz M. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Obstet Gynecol 2008;111:67–76
   PubMed Web of Science ®Google Scholar
• Simon J, Nachtigall L, Gut R, Lang E, Archer DF, Utian W. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. Obstet Gynecol 2008;112:1053–60
   PubMed Web of Science ®Google Scholar
• Griesser H, Skonietzki S, Fischer T, et al. Low dose estriol pessaries for the treatment of vaginal atrophy: a double-blind placebo-controlled trial investigating the efficacy of pessaries containing 0.2 mg and 0.03 mg estriol. Maturitas 2012;71:360–8
   PubMed Web of Science ®Google Scholar
• Cano A, Estévez J, Usandizaga R, et al. The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study. Menopause 2012;19:1130–9
   PubMed Web of Science ®Google Scholar
• Bachmann GA, Komi JO; Ospemifene Study Group. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause 2010;17:480–6
   PubMed Web of Science ®Google Scholar
• Goldstein SR, Bachmann GA, Koninckx PR, Lin VH, Portman DJ, Ylikorkala O; Ospemifene Study Group. Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy. Climacteric 2014;17:173–82
   PubMed Web of Science ®Google Scholar
• Portman DJ, Bachmann GA, Simon JA. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause 2013;20:623–30
   PubMed Web of Science ®Google Scholar
• Portman D, Palacios S, Nappi RE, Mueck AO. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial. Maturitas 2014;78:91–8
   PubMed Web of Science ®Google Scholar
• Henriksson L, Stjernquist M, Boquist L, Cedergren I, Selinus I. A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging. Am J Obstet Gynecol 1996;174:85–92
   PubMed Web of Science ®Google Scholar
• Naessen T, Rodriguez-Macias K. Endometrial thickness and uterine diameter not affected by ultralow doses of 17beta-estradiol in elderly women. Am J Obstet Gynecol 2002;186:944–7
   PubMed Web of Science ®Google Scholar
• Weisberg E, Ayton R, Darling G, et al. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric 2005;8:83–92
   PubMed Web of Science ®Google Scholar
• Gerbaldo D, Ferraiolo A, Croce S, Truini M, Capitanio GL. Endometrial morphology after 12 months of vaginal oestriol therapy in post-menopausal women. Maturitas 1991;13:269–74
   PubMed Web of Science ®Google Scholar
• Iosif CS. Effects of protracted administration of estriol on the lower genitourinary tract in postmenopausal women. Arch Gynecol Obstet 1992;251:115–20
   PubMed Web of Science ®Google Scholar
• Simon J, Nachtigall L, Ulrich LG, Eugster-Hausmann M, Gut R. Endometrial safety of ultra-low-dose estradiol vaginal tablets. Obstet Gynecol 2010;116:876–83
   PubMed Web of Science ®Google Scholar
• Ulrich LS, Naessen T, Elia D, Goldstein JA, Eugster-Hausmann M. Endometrial safety of ultra-low-dose Vagifem 10 μg in postmenopausal women with vaginal atrophy. Climacteric 2010;13:228–37
   PubMed Web of Science ®Google Scholar
• Smith P, Heimer G, Lindskog M, Ulmsten U. Oestradiol-releasing vaginal ring for treatment of postmenopausal urogenital atrophy. Maturitas 1993;16:145–54
   PubMed Web of Science ®Google Scholar
• Simon JA, Lin VH, Radovich C, Bachmann GA; Ospemifene Study Group. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause 2013;20:418–27
   PubMed Web of Science ®Google Scholar
• Berga SL. Profile of ospemifene in the breast. Reprod Sci 2013;20:1130–6
   PubMed Web of Science ®Google Scholar
• Vagifem summary of product characteristics. Vagifem 10 micrograms vaginal tablets. January 2015. Available from: https://www.medicines.org.uk/emc/print-document?documentId=23819 [last accessed 5 Sept 2016]
   Google Scholar
• Sahai H, Khurshid A. Formulas and tables for the determination of sample sizes and power in clinical trials for testing differences in proportions for the matched pair design: A review. Fundam Clin Pharmacol 1996;10:554–63
   PubMed Web of Science ®Google Scholar
• Medicines and Healthcare products Regulatory Agency. Public assessment report. Vagifem 10 micrograms vaginal tablets. February 2010. Available from http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con078939.pdf [last accessed 5 Sept 2016]
   Google Scholar
• Nolvadex (tamoxifen) tablets. Summary of product characteristics. Astra Zeneca UK Ltd, Luton, UK. May 2015. Available from: http://www.medicines.ie/medicine/4181/SPC/Nolvadex+D+20mg+Tablets/ [last accessed 5 Sept 2016]
   Google Scholar
• Conbriza (bazedoxifene) tablets. Summary of product characteristics. Pfizer Limited, Sandwich, Kent, UK. April 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000913/WC500033577.pdf [last accessed 5 Sept 2016]
   Google Scholar
• Raloxifene Teva (raloxifene hydrochloride) tablets. Summary of product characteristics. Teva B.V., Haarlem, The Netherlands. February 2015. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001075/WC500091420.pdf [last accessed 5 Sept 2016]
   Google Scholar